Cannabidiol (CBD) is the second-most prevalent cannabinoid after THC and the foremost subject of current research. Unlike its cousin tetrahydrocannabinol (THC), CBD doesn’t cause any intoxication. Instead, CBD works in synergy with our bodies in ways that modern science is just beginning to understand.

Most people don’t know that cannabinoids are already in our bodies. Phytocannabinoids (the cannabinoids in the plant) are simply mimicking endocannabinoids (the cannabinoids that naturally occur in our nervous and immune systems).29

Our cannabinoid neuronal receptors, first discovered in the 1980s, are specifically shaped to work with phytocannabinoids. These receptors, named CB1 and CB2, are spread throughout the body, with CB1 receptors concentrated in the brain and CB2 receptors more prevalent in the immune system.14

Our bodies produce two major endocannabinoids: anandamide and 2-arachidonoylglycerol. These compounds activate the endocannabinoid receptors or, alternately, block the receptors so other molecules can’t access them for a while. Blocking or activating the receptors modulates neurological and immune functions, and their action signals other biological processes that help maintain bodily homeostasis, otherwise known as balance.30

Anandamide, named from “ananda,” the Sanskrit word for bliss, is similar in effect to THC and responsible for exercise induced euphoria.31 It has important functions in brain circuits affecting mood, memory, and cognition;30 2-arachidonoylglycerol is far more abundant in our bodies than anandamide and strongly binds to both CB1 and CB2 receptors.32 While it doesn’t produce the pleasant effects of anandamide, it regulates synaptic functions to that having broad effects on neurotransmitters throughout the body.33

Human Body Endocannabinoid system CB1 and CB2 receptors



You’ve probably heard the news stories about medical marijuana. Maybe you’re curious. Even though the U.S. Food and Drug Administration doesn’t consider cannabis a medicine, consumers are reporting positive effects1 — and researchers are excited, too.

In 2016 and 2017, the National Institutes of Health spent $24 million researching cannabidiol (CBD).2 University research is piling up, too, and, as more positive patient stories pour in, consumers are adopting CBD at a rapid rate.

But at incredible CBD, we believe you should be more informed about your health care choices. Hopefully, this guide will help you learn more about cannabis medicines and if CBD products or cannabis medicines are right for you.

CBD: The New Superfood

People suffering from inflammation, chronic pain, seizures, mental health conditions, and other disorders are tired of expensive pharmaceutical medicines that, according to the Center for Disease Control,5 could have serious side effects. So, they’re trying CBD instead.

But it’s important to note that the U.S. Food and Drug Administration has not evaluated the medicinal efficacy of herbal supplements— or cannabidiol. Claiming that CBD can treat an illness is unlawful; reporting the findings of leading researchers isn’t. And, the latest research is worth reporting! It shows that CBD may have positive effects for people suffering from seizures, anxiety, arthritis, nausea, inflammation, cancer, and a host of other disorders.


  1. CBD Hemp Oil Benefits. Reviews & Testimonials. 2018.
  2. National Institutes for Health. Estimates of Funding for Various Research, Condition, and Disease Categories. 2017.
  3. Aizpurua-Olaizola, et al. Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes. 2016.
  4. Leafly. Cannabis Strain Explorer. 2018.
  5. Centers for Disease Control and Prevention. Understanding Side Effects and Adverse Events.2018.
  6. Mayo Clinic. Herbal supplements: what to know before you buy. 2018.
  7. Solinas, et al. Cannabidiol inhibits angiogenesis by multiple mechanisms. 2012.
  8. Ligresti, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. 2006.
  9. Massi, et al. Cannabidiol as potential anticancer drug. 2013.
  10. Porter; Jacobson. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. 2013.
  11. Tzadok, et al. CBD-enriched medical cannabis for intractable pediatric epilepsy: The current Israeli experience. 2016.
  12. Carlini, Cunha. Hypnotic and antiepileptic effects of cannabidiol. 1981.
  13. Sulak. 6 Common Myths and Controversies About High-CBD Cannabis. 2018.
  14. Pertwee. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. 2008.
  15. Schier, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. 2012.
  16. Crippa, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. 2011.
  17. Leweke, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. 2012.
  18. Costa, et al. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. 2007.
  19. Malfait, et al. The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine Collagen-Induced Arthritis. 2000.
  20. Hammell, et al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. 2016.
  21. Liou. Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation. 2010.
  22. Hampson, et al. Cannabidiol and ()Δ9-tetrahydrocannabinol are neuroprotective antioxidants. 1998.
  23. Xiong, et al. Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. 2011.
  24. Guzmán, et al. A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. 2006.
  25. Preet, et al. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. 2008.
  26. Caffarel, et al. Cannabinoids: a new hope for breast cancer therapy? 2012.
  27. National Cancer Institute. Cannabis and Cannabinoids (PDQ®)–Health Professional Version. 2018.
  28. Rahn. What Are the Side Effects of High-THC Cannabis? 2016.
  29. Cresco Labs. What is the endocannabinoid system? 2018.
  30. Joy, et al. Marijuana and Medicine: Assessing the Science Base. 1999.
  31. Fuss, et al. A runner’s high depends on cannabinoid receptors in mice. 2015.
  32. Sugiura, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. 1995.
  33. Kano, et al. Retrograde signaling at central synapses via endogenous cannabinoids. 2002.
  34. Penn Medicine. Penn Study Shows Nearly 70 Percent of Cannabidiol Extracts Sold Online Are Mislabeled. 2017.
  35. Steep Hill. Steep Hill Launches New High Detection Cannabis Pesticide Testing in California. 2016.